Skip to content
value.today

Altheus Therapeutics Inc

🇺🇸 Oklahoma City, Oklahoma, USABiotechnologyFounded 2006
Total raised
$10 M
2 rounds on record
Latest round
$8 M
Feb 2012
First round on record
May 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Altheus Therapeutics Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2012$8 MNo. 2$2 to $10 million

Altheus Therapeutics Inc: Raise no. 2, Feb 2012

Investors in this round

21 investors had bought by the notice of Jan 23, 2014: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
$967
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$200,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dayton T. Reardan · Executive Officer
  • Dennis Schafer · Executive Officer, Director
  • Richard F. Harty, MD · Executive Officer
  • Brian L. Clevinger · Director
  • Douglas A. Branch · Director
  • Thomas L. Shoaf · Director
  • William L. Paiva · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total amount was sold in multiple tranches. There was an additional $109,736 of the securities offered to current shareholders under a right of first refusal which was not exercised, and such amount will not be sold. The final tranche closed 1-6-14.”
  • On the use of proceeds: “Includes legal fees paid to a law firm affiliated with a director of the Company and deferred payments owed to certain of the Company's executive officers and directors.”

Signed by Douglas A. Branch, Secretary. Source: SEC Form D and 3 amendments, newest notice filed Jan 23, 2014. Read the notice at the SEC.

equity, optionsSEC
May 2009$2 MNo. 1Under $2 million

Altheus Therapeutics Inc: Raise no. 1, May 2009

Investors in this round

11 investors had bought by the notice of Dec 8, 2011: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$947
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$50,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian L. Clevinger · Executive Officer, Director
  • Dennis Schafer · Executive Officer, Director
  • Richard F. Harty, MD · Executive Officer, Promoter
  • Douglas A. Branch · Director
  • Thomas L. Shoaf · Director
  • William L. Paiva · Director
  • Alpha A. BioPartners, Inc. · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The maximum offering amount was originally $1,200,000 but was increased to $1,970,243.57 following the board and the note holders electing to add a fifth closing to the transaction.”

Signed by Douglas A. Branch, Secretary. Source: SEC Form D and 3 amendments, newest notice filed Dec 8, 2011. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Altheus Therapeutics Inc had no revenue when it filed its newest notice of a funding round (Jan 2014).

    SEC Form D (revenue range) · Jan 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2014

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Altheus Therapeutics Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Altheus Therapeutics Inc
NameRoleNamed in
Dayton T. ReardanExecutive officerJan 2014
Dennis SchaferExecutive officerJan 2014
Richard F. Harty, MDExecutive officerJan 2014
Brian L. ClevingerExecutive officerMar 2012
Brian L ClevingerExecutive officerJun 2010
Dennis L SchaferExecutive officerJun 2010
Douglas A BranchExecutive officerJun 2010
Richard F Harty, MDExecutive officerJun 2010
Brian L. ClevingerDirectorJan 2014
Dennis SchaferDirectorJan 2014
Douglas A. BranchDirectorJan 2014
Thomas L. ShoafDirectorJan 2014
William L. PaivaDirectorJan 2014
Brian L ClevingerDirectorJun 2010
Dennis L SchaferDirectorJun 2010
James L SchoeneckDirectorJun 2010
Thomas L ShoafDirectorJun 2010
William A PaivaDirectorJun 2010
Richard F. Harty, MDPromoterJan 2013
Alpha A. BioPartners, Inc.PromoterDec 2011
Alpha BioPartners, Inc.PromoterJun 2010
Richard F Harty, MDPromoterJun 2010